title: Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation.
abstract: Acute myelogenous leukemia (AML) with favorable cytogenetics responds well to chemotherapy. If the leukemia relapses, allogenic hematopoietic stem transplantation (allo-HSCT) is considered as a treatment option. Since the efficacy of reduced-intensity stem cell transplantation (RIST) for AML with favorable cytogenetics has not been established, we retrospectively analyzed the outcomes of allo-HSCT in AML patients according to cytogenetic risks. The outcome of allo-HSCT for AML patients with favorable cytogenetics seemed to be superior to that for AML patients with intermediate cytogenetics. In AML patients with favorable cytogenetics, the 3-year overall survival (OS) and relapse-free survival (RFS) rates were 88 and 76%, respectively, in the RIST group. Both the 3-year OS and RFS rates were 81% in the conventional stem cell transplantation (CST) group. The outcome of RIST for AML patients with favorable cytogenetics was comparable to that for patients who received CST despite the more advanced age and greater organ dysfunction in RIST group than in CST group. None of the patients died within 90 days after RIST. Moreover, there was no relapse in patients with favorable cytogenetics who were in hematological remission prior to RIST. Thus, RIST for AML patients with favorable cytogenetics in remission is safe and effective.
authors.affiliation: Stem Cell Transplantation Center, Hokkaido University Hospital, Sapporo 060-8648, Japan. t-kondoh@med.hokudai.ac.jp
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kondo
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yasumoto
authors.forename: Kotaro
authors.initials: K
authors.lastname: Arita
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Sugita
authors.forename: Akio
authors.initials: A
authors.lastname: Shigematsu
authors.forename: Kohei
authors.initials: K
authors.lastname: Okada
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Takahata
authors.forename: Masahiro
authors.initials: M
authors.lastname: Onozawa
authors.forename: Kaoru
authors.initials: K
authors.lastname: Kahata
authors.forename: Yukari
authors.initials: Y
authors.lastname: Takeda
authors.forename: Masato
authors.initials: M
authors.lastname: Obara
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Endo
authors.forename: Mitsufumi
authors.initials: M
authors.lastname: Nishio
authors.forename: Norihiro
authors.initials: N
authors.lastname: Sato
authors.forename: Junji
authors.initials: J
authors.lastname: Tanaka
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hashino
authors.forename: Takao
authors.initials: T
authors.lastname: Koike
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Imamura
mesh_terms: D000328:Adult; D000368:Aged; D003582:Cytogenetics; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods*; D055815:Young Adult